Unexpected detection of melanoma brain metastasis by PET with iodine-124 betaCIT

Area of Science:

• Neuroimaging
• Nuclear Medicine
• Oncology

Background:

• Iodine-124-beta-carbomethoxy-3beta(4-iodophenyl)tropane (I-124 betaCIT) is a radiotracer used for positron emission tomography (PET) scans.
• It primarily targets dopamine transporters, aiding in the diagnosis of Parkinsonian syndromes.
• Parkinson disease is characterized by the loss of dopaminergic neurons in the striatum.

Observation:

• A PET scan with I-124 betaCIT was performed on a patient with suspected early Parkinson disease.
• The scan revealed normal striatal uptake but an unexpected focal uptake in the left parietal cortex.
• Subsequent MRI identified a corresponding nodular lesion, later diagnosed as malignant metastatic melanoma.

Findings:

• The focal I-124 betaCIT uptake in the parietal cortex indicated specific binding to the lesion.
• This suggests that I-124 betaCIT can bind to melanoma brain metastases.
• The patient was diagnosed with metastatic melanoma, not Parkinson disease.

Implications:

• I-124 betaCIT PET imaging may have a role in detecting brain metastases from melanoma.
• This tracer's utility may extend beyond neurodegenerative diseases to oncological imaging.
• Further research is warranted to explore the diagnostic potential of I-124 betaCIT in metastatic brain tumors.